VistaGen Therapeutics, a biotechnology company in suburban San Francisco, has signed a deal to use human embryonic stem cell patents from the Wisconsin Alumni Research Foundation.
VistaGen, which is located in South San Francisco, Calif., will use the license to accelerate its commercial programs focused on using stem cells as next-generation tools for predictive toxicology and drug discovery screenings.